Trial · NCT00416351
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT00416351, Phase 1, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2022-05-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment. Trials, record NCT00416351. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00416351
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
- NCT number
- NCT00416351
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Leukemia, Lymphoma, Small Intestine Cancer
- Interventions
- clofarabine
- First posted
- 2006-12-28
- Last updated
- 2022-05-17
- Results first posted
- 2022-05-17
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose | 2 years | |
| Primary | Response Rate for Participants With Non-Hodgkin's Lymphoma | 2 years | Response rate as defined by complete remission, complete remission unconfirmed, partial remission, positron emission tomography (PET)-negative partial remission, stable disease, and progressive disease (Phase II) |
| Secondary | Participants Evaluated for Toxicity | 2 years | Toxicity as defined by NCI Common Terminology Criteria for Adverse Events v 3.0 |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Tolerated Dose | 2 years | mg/m2 of clofarabine | NUMBER | |
| PRIMARY | Response Rate for Participants With Non-Hodgkin's Lymphoma | 2 years | Evaluable participants with Non-Hodgkin's Lymphoma | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Participants Evaluated for Toxicity | 2 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose | Clofarabine | 20 | mg/m2 of clofarabine | ||
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 4 mg/m2/Day Clofarabine | Complete Response | 0 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 8 mg/m2/Day Clofarabine | Complete Response | 1 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 13.2 mg/m2/Day Clofarabine | Complete Response | 1 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 20 mg/m2/Day Clofarabine | Complete Response | 1 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 28 mg/m2/Day Clofarabine | Complete Response | 0 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 4 mg/m2/Day Clofarabine | Partial Response (PR) | 0 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 8 mg/m2/Day Clofarabine | Partial Response (PR) | 0 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 13.2 mg/m2/Day Clofarabine | Partial Response (PR) | 0 | Participants | |
| Response Rate for Participants With Non-Hodgkin's Lymphoma | 20 mg/m2/Day Clofarabine | Partial Response (PR) | 1 | Participants |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 results by groupParticipant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 4 mg/m2/Day Clofarabine | 1 | |
| Overall Study | STARTED | 8 mg/m2/Day Clofarabine | 3 | |
| Overall Study | STARTED | 13.2 mg/m2/Day Clofarabine | 4 | |
| Overall Study | STARTED | 20 mg/m2/Day Clofarabine | 17 | |
| Overall Study | STARTED | 28 mg/m2/Day Clofarabine | 4 | |
| Overall Study | COMPLETED | 4 mg/m2/Day Clofarabine | 1 | |
| Overall Study | COMPLETED | 8 mg/m2/Day Clofarabine | 3 | |
| Overall Study | COMPLETED | 13.2 mg/m2/Day Clofarabine | 4 | |
| Overall Study | COMPLETED | 20 mg/m2/Day Clofarabine | 17 | |
| Overall Study | COMPLETED | 28 mg/m2/Day Clofarabine | 4 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events375
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | 4 mg/m2/Day Clofarabine | 1 | 1 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | 8 mg/m2/Day Clofarabine | 2 | 3 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | 13.2 mg/m2/Day Clofarabine | 2 | 4 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | 20 mg/m2/Day Clofarabine | 2 | 17 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | 28 mg/m2/Day Clofarabine | 3 | 4 | |
| other | Dyspnea (shortness of breath) | Respiratory, thoracic and mediastinal disorders | 4 mg/m2/Day Clofarabine | 0 | 1 | |
| other | Dyspnea (shortness of breath) | Respiratory, thoracic and mediastinal disorders | 8 mg/m2/Day Clofarabine | 0 | 3 | |
| other | Dyspnea (shortness of breath) | Respiratory, thoracic and mediastinal disorders | 13.2 mg/m2/Day Clofarabine | 0 | 4 | |
| other | Dyspnea (shortness of breath) | Respiratory, thoracic and mediastinal disorders | 20 mg/m2/Day Clofarabine | 0 | 17 | |
| other | Dyspnea (shortness of breath) | Respiratory, thoracic and mediastinal disorders | 28 mg/m2/Day Clofarabine | 3 | 4 |
1 to 10 of 375Source ClinicalTrials.gov
See all 375 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 4 mg/m2/Day Clofarabine | 1 | 1 |
| Total, all-cause mortality | 8 mg/m2/Day Clofarabine | 3 | 3 |
| Total, all-cause mortality | 13.2 mg/m2/Day Clofarabine | 3 | 4 |
| Total, all-cause mortality | 20 mg/m2/Day Clofarabine | 12 | 17 |
| Total, all-cause mortality | 28 mg/m2/Day Clofarabine | 4 | 4 |
| Total, other adverse events | 4 mg/m2/Day Clofarabine | 1 | 1 |
| Total, other adverse events | 8 mg/m2/Day Clofarabine | 3 | 3 |
| Total, other adverse events | 13.2 mg/m2/Day Clofarabine | 4 | 4 |
| Total, other adverse events | 20 mg/m2/Day Clofarabine | 17 | 17 |
| Total, other adverse events | 28 mg/m2/Day Clofarabine | 4 | 4 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | Rudin, Charles M. | SLOAN-KETTERING INST CAN RESEARCH | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00416351
GET https://conductscience.org/api/trials/v1/NCT00416351/results?page=2